Apart from cancer immunotherapy, blocking IgG1 antibodies targeting CD40L for the therapy of autoimmune diseases has also been shown to cause cardiovascular thrombotic events in clinical studies [47]. This evidence concerns the gene CD40LG and autoimmune disease.